Liam Payne's Blood Alcohol Content At Time of Death Near Lethal Levels
Liam Payne's blood alcohol level was more than three times the limit allowed while driving in the United States at the time of the singer's death from a 40-foot fall in Buenos Aires, Argentina in October. The results were included in a report from the National Criminal and Correctional Prosecutor's Office No. 14 released on Friday, which showed that an autopsy found that the former One Direction member and solo star had 'alcohol concentrations of up to 2.7 grams per liter in blood' at the time of his death.
While Payne, 31, was not driving at the time, for context, the legal blood alcohol content (BAC) in the U.S. for drivers over 21 is 0.08%; 2.7 grams per liter translates to 0.27% BAC, which is more than three times the U.S. driving limit.
More from Billboard
Netflix to Proceed with 'Building the Band' Series in Wake of Liam Payne's Death
Tia Ray to Perform at 2025 SXSW Music Festival
Here Are the Lyrics to Chappell Roan's 'Pink Pony Club'
According to the American Addiction Centers' Alcohol.org, that BAC can cause, 'confusion, feeling dazed, and disorientation… Sensations of pain will change, so if you fall and seriously hurt yourself, you may not notice, and you are less likely to do anything about it.' Other potential effects include: blackouts, nausea, vomiting and impairment of the gag reflex, 'which could cause choking or aspirating on vomit.'
The Cleveland Clinic also notes that while a BAC of 0.15%-0.30% can cause the above symptoms and drowsiness, Payne's measured level was just below the BAC (0.30%-0.40%) that can cause alcohol poisoning, 'a potentially life-threatening condition… [which can cause a] loss of consciousness.'
The Argentinian report noted that in addition to the dangerous BAC, the autopsy revealed that Payne — whose death it said was a result of 'multiple trauma and internal and external bleeding' caused by a fall from a three-story hotel balcony — also had cocaine metabolites, methylecgonine, benzoylecgomine, cocaethylene and the medication sertraline (Zoloft).
The prosecutor's office announced in November that a toxicology report said Payne had 'alcohol, cocaine and prescription antidepressants' in his system when he died on Oct. 16.
Last week, an Argentinian court dropped charges of criminal negligence against three of the five people indicted in connection with Payne's death. The court cleared the head receptionist at the CasaSur Hotel, Esteban Grassi, Argentinian-American businessman Rogelio Nores, a friend who accompanied Payne on the trip, and Gilda Martin, the hotel's manager. Grassi made two emergency calls prior to the deadly accident, first reporting that a guest was 'trashing the entire room' and later expressing concerns that the guest 'may be in danger.'
In a recent Rolling Stone exposé, Payne's former girlfriend, model Maya Henry, described the singer's longtime struggles with depression and addiction, saying he became 'someone unrecognizable' when he was using substances.
Best of Billboard
Chart Rewind: In 1989, New Kids on the Block Were 'Hangin' Tough' at No. 1
Janet Jackson's Biggest Billboard Hot 100 Hits
H.E.R. & Chris Brown 'Come Through' to No. 1 on Adult R&B Airplay Chart
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Axios
a day ago
- Axios
Exclusive: PBM trade group sues Arkansas over pharmacy law
The trade group representing pharmacy benefit managers sued on Monday to overturn a first-in-the-nation state law that prevents them from owning pharmacies in Arkansas. Why it matters: The Pharmaceutical Care Management Association's lawsuit adds to legal challenges to the ownership ban and comes as other states consider similar policies that blame large drug-price middlemen for rising pharmaceutical prices. Navitus Health Solutions, a PBM that's not a member of the trade association, is also a plaintiff in the lawsuit. CVS Health and Cigna, two of the largest PBMs, have filed their own complaints against the law. What they're saying: The law "will disrupt the way patients, especially patients with very complex medical conditions, receive their medication, and it will require consumers in Arkansas to find new pharmacies," said Katie Payne, senior vice president of public affairs and head of advocacy at PCMA. More than 40 retail pharmacies in Arkansas that together fill millions of prescriptions each year will have to cease operation under the law, according to the complaint. Payne said that the law will worsen drug affordability in the state by prohibiting out-of-state companies from running pharmacies that offer lower-cost options. However, PCMA did not have projections on how Arkansas's law will affect drug prices in the state. Zoom in: The lawsuit claims that Arkansas's policy gives preferential treatment to pharmacies based in the state, violating the Constitution's dormant Commerce Clause and Privileges and Immunities Clause. It also says the law improperly declares PBMs guilty of antitrust violations and delivers punishment without a trial. "Rather than innovating and attempting to compete with PBM pharmacies on the merits, many independent pharmacies have turned to state lawmakers to manipulate the market with the heavy hand of government, to artificially tip the scales of competition in their favor," the complaint alleges. Arkansas Gov. Sarah Huckabee Sanders (R) has said the law is necessary to hold PBMs accountable for anticompetitive actions. Lawmakers at the state and federal level are increasingly questioning large pharmacy benefit managers like CVS Caremark, Express Scripts and Optum Rx's outsize role in the pharmaceutical supply chain and whether they're contributing to high drug prices. Between the lines: PCMA's complaint notes that an earlier version of the bill would have required Walmart — Arkansas's largest company — to close its pharmacies as well, since the company administers its own pharmacy benefits for employees. State legislators amended the policy before it was passed so Walmart would no longer be subject to the law.
Yahoo
a day ago
- Yahoo
Axsome Therapeutics Provides Update on the New Drug Application (NDA) for AXS-14 for the Management of Fibromyalgia
NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it has received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for AXS-14 (esreboxetine) for the management of fibromyalgia. The FDA states that upon preliminary review, it found that the NDA was not sufficiently complete to permit a substantive review. Specifically, the FDA does not consider the second of the two placebo-controlled trials in the submission to be adequate and well-controlled because its primary endpoint was at 8 weeks and it used a flexible-dose paradigm. The FDA indicated that the first of the two placebo-controlled trials in the submission, which utilized a 12-week endpoint and a fixed-dose paradigm, is adequate and well-controlled. The FDA did not raise any questions relating to the positive results of the studies, both of which met their primary endpoints. To address the FDA's feedback, Axsome will conduct an additional controlled trial, which will use a fixed-dose paradigm and a 12-week primary endpoint as requested by the FDA. Axsome anticipates initiating this trial in the fourth quarter of 2025. 'The clear feedback provided by the FDA's Division of Anesthesiology, Addiction Medicine, and Pain Medicine allows us to move expeditiously with the continued development of this important investigational medicine for the approximately 17 million patients in the U.S. living with fibromyalgia. We are well positioned to initiate a new controlled trial that will incorporate the FDA's feedback by the end of 2025,' said Herriot Tabuteau, MD, Chief Executive Officer of Axsome. 'As highlighted in the FDA's Patient-Focused Drug Development Initiative report The Voice of the Patient: Fibromyalgia, patients with fibromyalgia experience debilitating widespread pain, fatigue, and functional impairment, and report living with constant stigmatization, anxiety, depression, and fear of ongoing or worsening symptoms. We are excited and motivated by the potential for AXS-14 to address this high unmet medical need for patients, as evidenced by the consistent efficacy demonstrated to date across a broad range of fibromyalgia symptoms, including significant improvements in pain, function, and fatigue, in the completed trials.' About AXS-14 AXS-14 (esreboxetine) is a highly selective and potent norepinephrine reuptake inhibitor for the management of fibromyalgia and other conditions. Esreboxetine, the SS-enantiomer of reboxetine, is more potent and selective than racemic reboxetine. AXS-14 is an investigational drug product not approved by the FDA. About Fibromyalgia Fibromyalgia is a chronic debilitating disorder characterized by widespread pain, fatigue, disturbed sleep, depression, and cognitive impairment.1 Other symptoms of this disorder can include tingling in the hands and feet and headaches.1 Fibromyalgia has considerable detrimental effects on physical, emotional, social, and day-to-day functioning.1 Fibromyalgia is considered to be mediated mainly in the central nervous system. Approximately 17 million Americans, 90% of whom are women, are estimated to suffer from fibromyalgia.2 Treatment options for fibromyalgia are limited with only three pharmacologic treatments currently approved by the FDA. About Axsome Therapeutics Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Our industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, and multiple late-stage development programs addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in the United States. Together, we are on a mission to solve some of the brain's biggest problems so patients and their loved ones can flourish. For more information, please visit us at and follow us on LinkedIn and X. Forward Looking Statements Certain matters discussed in this press release are 'forward-looking statements'. The Company may, in some cases, use terms such as 'predicts,' 'believes,' 'potential,' 'continue,' 'estimates,' 'anticipates,' 'expects,' 'plans,' 'intends,' 'may,' 'could,' 'might,' 'will,' 'should' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company's statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the commercial success of the Company's SUNOSI®, AUVELITY®, and SYMBRAVO® products and the success of the Company's efforts to obtain any additional indication(s) with respect to solriamfetol and/or AXS-05; the Company's ability to maintain and expand payer coverage; the success, timing and cost of the Company's ongoing clinical trials and anticipated clinical trials for the Company's current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company's ability to fully fund the Company's disclosed clinical trials, which assumes no material changes to the Company's currently projected revenues or expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of the Company's ongoing clinical trials, and/or data readouts, and the number or type of studies or nature of results necessary to support the filing of a new drug application ('NDA') for any of the Company's current product candidates; the Company's ability to fund additional clinical trials to continue the advancement of the Company's product candidates; the timing of and the Company's ability to obtain and maintain U.S. Food and Drug Administration ('FDA') or other regulatory authority approval of, or other action with respect to, the Company's product candidates, including statements regarding the timing of any NDA submission; the Company's ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the Company's ability to successfully resolve any intellectual property litigation, and even if such disputes are settled, whether the applicable federal agencies will approve of such settlements; the successful implementation of the Company's research and development programs and collaborations; the success of the Company's license agreements; the acceptance by the market of the Company's products and product candidates, if approved; the Company's anticipated capital requirements, including the amount of capital required for the commercialization of SUNOSI, AUVELITY, and SYMBRAVO and for the Company's commercial launch of its other product candidates, if approved, and the potential impact on the Company's anticipated cash runway; the Company's ability to convert sales to recognized revenue and maintain a favorable gross to net sales; unforeseen circumstances or other disruptions to normal business operations arising from or related to domestic political climate, geo-political conflicts or a global pandemic and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances. Investors:Mark JacobsonChief Operating Officer(212) 332-3243mjacobson@ Media:Darren OplandDirector, Corporate Communications(929) 837-1065dopland@ References: Matthew J. Bair, Erin E. Krebs. Fibromyalgia. Ann Intern Med. 2020;172:ITC33-ITC48. doi:10.7326/AITC202003030 Vincent A, et al. Prevalence of fibromyalgia: a population-based study in Olmsted County, Minnesota, utilizing the Rochester Epidemiology Project. Arthritis Care Res (Hoboken). 2013 May;65(5):786-92. doi: 10.1002/ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Yahoo
Man dies after tree falls on top of car in northeast GA
The Georgia State Patrol has identified a man who was killed in a car wreck over the weekend. [DOWNLOAD: Free WSB-TV News app for alerts as news breaks] On Saturday, around 6:48 p.m., GSP was called to the area of State Route 51 near Garrison Road in Banks County. When troopers arrived, they learned that Jason Keith Payne, 56, of Carnesville, was driving a 2000 Nissan Altima. Officials said that while Payne was traveling eastbound, a tree on the south side of State Route 51 fell across the road, hitting the top of the car. Payne was pronounced dead at the scene. According to GEMA, the 56-year-old is believed to have been killed when a line of storms moved through metro Atlanta on Saturday, bringing damaging winds and heavy rain. Gov. Brian Kemp shared his condolences in a post on X. TRENDING STORIES: Atlanta-area rapper sentenced for bringing stolen loaded 'machine gun' into hospital labor unit A runaway pet zebra has been captured in Tennessee 38-year-old GA man charged with grooming a minor [SIGN UP: WSB-TV Daily Headlines Newsletter]
